"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Completing Administration of the First Subject in the Global Multicenter Phase‑III Clinical Trial of BL‑M14D1 (DLL3 ADC) for Injection Combined With Immunotherapy as First‑line Treatment for Extensive‑stage Small Cell Lung Cancer

Announcement on Voluntary Disclosure of Completing Administration of the First Subject in the Global Multicenter Phase‑III Clinical Trial of BL‑M14D1 (DLL3 ADC) for Injection Combined With Immunotherapy as First‑line Treatment for Extensive‑stage Small Cell Lung Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment